Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers.

Chen Y, Zhang W, Huang WH, Tan ZR, Wang YC, Huang X, Zhou HH.

Eur J Clin Pharmacol. 2013 Nov;69(11):1933-8. doi: 10.1007/s00228-013-1554-0. Epub 2013 Jul 7.

PMID:
23831870
2.

Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin.

Hu M, Mak VW, Yin OQ, Chu TT, Tomlinson B.

Drug Metab Pharmacokinet. 2013;28(2):104-8. Epub 2012 Jul 31.

3.

Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.

Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, Dempsey C, Rasmussen S, Houle R, Chan G, Cai X, Valesky R, Fraser IP, Stoch SA.

Br J Clin Pharmacol. 2014 Sep;78(3):587-98. doi: 10.1111/bcp.12377.

4.

OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers.

Wen J, Xiong Y.

J Clin Pharm Ther. 2010 Feb;35(1):99-104. doi: 10.1111/j.1365-2710.2009.01071.x.

PMID:
20175818
5.

Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.

Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG, Jang IJ.

Clin Pharmacol Ther. 2005 Oct;78(4):342-50.

PMID:
16198653
6.
7.

SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.

Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y.

Clin Pharmacol Ther. 2007 Nov;82(5):541-7. Epub 2007 Apr 25.

PMID:
17460607
8.

Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males.

Zhu J, Song M, Tan HY, Huang LH, Huang ZJ, Liu C, Fu ZM, Huang YY, Tan ZR, Chen XP, Yuan H, Yang GP.

Pak J Pharm Sci. 2013 May;26(3):577-84.

PMID:
23625433
9.

Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1α, did not increase the systemic exposure of pitavastatin.

Lee HI, Choi CI, Sa JH, Lee YJ, Bae JW, Jang CG, Lee SY.

Int J Clin Pharmacol Ther. 2014 Nov;52(11):981-5. doi: 10.5414/CP201849.

PMID:
25138679
10.

Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment.

Wu LX, Guo CX, Chen WQ, Yu J, Qu Q, Chen Y, Tan ZR, Wang G, Fan L, Li Q, Zhang W, Zhou HH.

Br J Clin Pharmacol. 2012 May;73(5):750-7. doi: 10.1111/j.1365-2125.2011.04150.x.

11.

effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.

Lau YY, Huang Y, Frassetto L, Benet LZ.

Clin Pharmacol Ther. 2007 Feb;81(2):194-204. Epub 2006 Dec 27.

PMID:
17192770
12.

Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans.

Oh ES, Kim CO, Cho SK, Park MS, Chung JY.

Drug Metab Pharmacokinet. 2013;28(3):196-202. Epub 2012 Sep 25.

13.

The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.

Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH, Shin JG.

Pharmacogenet Genomics. 2008 May;18(5):424-33. doi: 10.1097/FPC.0b013e3282fb02a3.

PMID:
18408565
14.

Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.

Allred AJ, Bowen CJ, Park JW, Peng B, Williams DD, Wire MB, Lee E.

Br J Clin Pharmacol. 2011 Aug;72(2):321-9. doi: 10.1111/j.1365-2125.2011.03972.x.

15.

Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase.

Fujino H, Saito T, Ogawa S, Kojima J.

J Pharm Pharmacol. 2005 Oct;57(10):1305-11.

PMID:
16259759
16.

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.

Niemi M, Pasanen MK, Neuvonen PJ.

Clin Pharmacol Ther. 2006 Oct;80(4):356-66.

PMID:
17015053
17.

Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase.

Fujino H, Nakai D, Nakagomi R, Saito M, Tokui T, Kojima J.

Arzneimittelforschung. 2004;54(7):382-8.

PMID:
15344842
18.

Comparison of scaled-average, population, and individual bioequivalence on 2 tablets of pitavastatin calcium: a 3-period, reference-replicated, crossover study in healthy Chinese volunteers.

Huang YH, Li ZQ, Pan GX, Li YF, Liu Y, Sun JX, Gu XF, Li N, Wang BH.

Clin Ther. 2014 Sep 1;36(9):1205-1216.e6. doi: 10.1016/j.clinthera.2014.06.021.

PMID:
25234550
19.

Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin.

Choi CI, Lee YJ, Lee HI, Kim BH, Kim MJ, Jang CG, Bae JW, Lee SY.

Xenobiotica. 2012 May;42(5):496-501. doi: 10.3109/00498254.2011.632030. Epub 2011 Nov 11.

PMID:
22077103
20.

Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.

Backman JT, Luurila H, Neuvonen M, Neuvonen PJ.

Clin Pharmacol Ther. 2005 Aug;78(2):154-67.

PMID:
16084850

Supplemental Content

Support Center